Sirtuins and NAD+: How SIRT1-SIRT7 Translate NAD+ Levels Into Longevity Signaling

Sirtuins are why NAD+ levels matter. The seven mammalian sirtuins (SIRT1-SIRT7) are NAD+-dependent enzymes that translate the cell's moment-to-moment NAD+ concentration into changes in gene expression, mitochondrial efficiency, DNA repair, and stress response. When NAD+ falls, sirtuin output falls with it — which is the mechanistic bridge between “NAD+ decline” and almost every downstream aging phenotype researchers have linked to NAD+ biology.

What are sirtuins, in plain terms?

Sirtuins are a conserved family of enzymes that strip acetyl (and other acyl) groups off proteins. That sounds boring until you realize which proteins they act on: transcription factors (p53, FOXO, NF-κB), DNA repair scaffolds (KAP1, PARP1), histone tails (H3K9, H3K56), metabolic enzymes (acetyl-CoA synthetase, long-chain acyl-CoA dehydrogenase), and mitochondrial regulators (PGC-1α, SOD2). By deacylating these targets, sirtuins switch entire cellular programs on or off.

The catch — and the reason this gets discussed in NAD+ articles at all — is that every deacylation reaction consumes one molecule of NAD+. The enzyme cleaves NAD+ into nicotinamide plus an O-acetyl-ADP-ribose intermediate. No NAD+ means no sirtuin catalysis. This is the molecular reason age-related NAD+ decline translates into reduced sirtuin output even when sirtuin protein levels stay constant.

The seven mammalian sirtuins differ in where they live and what they deacylate:

• SIRT1 (nucleus, cytoplasm) — the most-studied sirtuin. Deacetylates p53, FOXO1/3, PGC-1α, NF-κB, and histones. Governs metabolic adaptation, stress resistance, and inflammation.
• SIRT2 (cytoplasm, transient nuclear) — deacetylates α-tubulin and regulates cell-cycle progression. Tumor-suppressor and tumor-promoter roles depending on tissue context.
• SIRT3 (mitochondria) — the dominant mitochondrial deacetylase. Controls the acetylation state of ~65% of mitochondrial proteins (Hebert et al. 2013, PMID: 23806337). Regulates fatty acid oxidation, the urea cycle, oxidative phosphorylation, and ROS defense via SOD2.
• SIRT4 (mitochondria) — primarily an ADP-ribosyl transferase and lipoamidase; weak deacetylase. Restrains glutamine metabolism.
• SIRT5 (mitochondria, cytoplasm) — desuccinylates, demalonylates, and deglutarylates rather than deacetylates. The functional consequences are still being worked out.
• SIRT6 (nucleus, chromatin-associated) — the strongest single longevity-extending sirtuin in mammalian overexpression studies. Deacetylates H3K9 at telomeres and pericentric heterochromatin, regulates glucose metabolism, and represses inflammatory gene expression.
• SIRT7 (nucleolus) — deacetylates H3K18 and regulates ribosomal RNA transcription. Linked to genome integrity and oncogenic transformation programs.

Why sirtuins entered the longevity literature

The thread starts in yeast. Kaeberlein, McVey, and Guarente (1999, PMID: 10465783) showed that overexpressing the yeast sirtuin Sir2 extended replicative lifespan, and deleting it shortened lifespan. Caloric restriction — the most reliable lifespan extender known in almost every model organism tested — required Sir2 to produce its full effect in yeast (Lin, Defossez, Guarente 2000, PMID: 11000115). This linked a single enzyme to two of the deepest questions in aging research at once.

The story scaled to invertebrates. Tissenbaum and Guarente (2001, PMID: 11242085) extended C. eleganslifespan by overexpressing sir-2.1, the worm sirtuin homolog. Drosophila Sir2 overexpression produced similar effects (Rogina and Helfand 2004, PMID: 15596721). At this point sirtuins looked like a candidate “master longevity gene” — a single switch coordinating metabolic state and lifespan across kingdoms.

The mammalian translation has been messier and more interesting. Not every sirtuin extends lifespan in mice when overexpressed; not every knockout shortens it. The story split by family member, and that is where most current research lives. SIRT1 is the most studied. SIRT3 is the mitochondrial workhorse. SIRT6 has the strongest direct lifespan evidence.

SIRT1: the nuclear regulator everyone knows by name

SIRT1 is the mammalian Sir2 ortholog and the sirtuin people usually mean when they say “sirtuin.” It deacetylates a long list of substrates that includes p53 (Vaziri et al. 2001, PMID: 11672522), FOXO transcription factors (Brunet et al. 2004, PMID: 14976264), NF-κB (Yeung et al. 2004, PMID: 15152190), and PGC-1α (Rodgers et al. 2005, PMID: 15744310). Through these substrates SIRT1 modulates apoptosis, oxidative-stress resistance, inflammation, and mitochondrial biogenesis.

SIRT1 activity rises during caloric restriction and falls under high-fat-diet conditions in mice. SIRT1-knockout mice are not viable on most genetic backgrounds; tissue-specific knockouts show metabolic dysfunction, increased inflammatory tone, and reduced stress-resistance. Whole-body SIRT1 overexpression in mice extends healthspan markers — insulin sensitivity, glucose tolerance, motor function — but produces only modest median-lifespan extension in some studies and none in others (Herranz et al. 2010, PMID: 20975741).

The cleanest single result: SIRT1 overexpression in male mice protects against age-related metabolic disease but does not consistently extend maximum lifespan. SIRT1 looks more like a healthspan modifier in mammals than a master longevity gene. That is still consequential — but the framing in popular coverage has tended to overshoot the biology.

SIRT3: the mitochondrial deacetylase

SIRT3 is the dominant deacetylase inside mitochondria. Hebert and colleagues (2013, PMID: 23806337) showed that knocking out SIRT3 in mice produces hyperacetylation of ~65% of all mitochondrial proteins — an extraordinary share. The functional consequences map cleanly to what mitochondria need to do: fatty acid oxidation slows, ATP synthesis efficiency drops, and the antioxidant defense enzyme SOD2 becomes less active without SIRT3 deacetylation.

SIRT3 expression declines with age in skeletal muscle, heart, and liver in rodent studies. Lombard et al. (2007, PMID: 17923681) and subsequent groups have documented that SIRT3-knockout mice develop accelerated cardiac hypertrophy, fatty liver under high-fat feeding, and impaired thermogenic responses. SIRT3 deficiency does not kill mice outright but consistently degrades the mitochondrial response to metabolic stress.

For NAD+ supplementation specifically, SIRT3 is the most plausible downstream beneficiary. Mitochondrial NAD+ is a separate pool from the cytoplasmic and nuclear pools, and several lines of evidence suggest mitochondrial NAD+ falls with age independently of cytoplasmic NAD+. Cantó et al. (2012, PMID: 22682224) showed that NR supplementation in mice raised mitochondrial NAD+ and improved exercise performance through a SIRT3-dependent mechanism. Whether this mechanism is operative at the doses humans actually take remains under-studied.

The mitochondrial acetylome problem

One way to appreciate why SIRT3 matters: aging shifts the mitochondrial acetylome — the inventory of acetylated proteins — toward hyperacetylation. Many of those acetylation marks inhibit enzyme activity. So an aging mitochondrion is one running on increasingly “braked” enzymes. SIRT3 is the brake-release mechanism. If SIRT3 activity drops because NAD+ drops, brakes stay applied. This is the cleanest mechanistic narrative connecting NAD+ decline to mitochondrial dysfunction in aging.

SIRT6: the genome guardian with the longest lifespan record

SIRT6 is the sirtuin with the strongest single lifespan evidence in mammals. Kanfi et al. (2012, PMID: 22367546) reported that SIRT6-transgenic male mice lived ~15% longer than wild-type littermates at the median; the effect was male-specific and not observed in females. Subsequent work (Roichman et al. 2021, PMID: 34290260) showed SIRT6 overexpression in both sexes extended lifespan when initiated earlier and in a different transgenic background.

SIRT6 deacetylates H3K9 and H3K56 at telomeres and at heterochromatin. It also represses transcription of glycolytic genes and inflammatory cytokines, and it recruits to double-strand breaks to promote DNA repair. SIRT6-knockout mice age dramatically: they develop a progeroid phenotype by 3-4 weeks and die by ~4 weeks of age (Mostoslavsky et al. 2006, PMID: 16439206) from a syndrome that resembles premature aging in humans.

The progeroid SIRT6-knockout phenotype is one of the most striking single-gene aging phenotypes in mouse genetics. It is also a cautionary data point: total loss of a single sirtuin produces accelerated aging, but it does not follow that adding more of it reverses normal aging. Overexpression studies show benefit but at much smaller magnitudes than the knockout disease.

Sirtuin family at a glance

A side-by-side reference for which sirtuin does what, where it lives, and what its strongest aging-related evidence looks like:

Resveratrol, STACs, and the sirtuin-activator controversy

The most contentious thread in sirtuin biology is whether direct small-molecule activators of sirtuins exist and work in humans. Howitz, Bitterman, and colleagues (2003, PMID: 12939617) reported that resveratrol — a polyphenol from grape skins — activates SIRT1 in vitro. The result kicked off a decade of resveratrol-focused longevity research and a billion-dollar acquisition (GSK/Sirtris in 2008).

The mechanism turned out to be more complicated. Pacholec et al. (2010, PMID: 20023728) showed that resveratrol's SIRT1 activation depended on the fluorophore used in the assay substrate; with a native peptide substrate, the effect largely disappeared. This triggered an extended scientific argument. Hubbard and colleagues (2013, PMID: 23502421) then showed that the resveratrol effect is real but requires substrates containing a hydrophobic residue near the acetyl-lysine — a structural requirement that explains why some assays showed activation and others did not.

The current synthesis: resveratrol can activate SIRT1 against a subset of natural substrates, but pharmacokinetics in humans (low oral bioavailability, rapid glucuronidation) make achieving sirtuin-activating concentrations difficult. Resveratrol clinical trials have shown modest metabolic effects in some studies and null results in others. It is not a uniformly potent SIRT1 activator at oral doses humans realistically take.

A separate class of designed sirtuin-activating compounds (STACs) — SRT1720, SRT2104, SRT2379 — emerged from medicinal-chemistry optimization at Sirtris and later GSK. These compounds bind a specific N-terminal allosteric site on SIRT1 and produce substrate-independent activation. Human clinical data has been mixed: SRT2104 produced modest improvements in lipid profiles in healthy older adults (Libri et al. 2012, PMID: 23145085) but no flagship clinical successes have emerged.

Will NAD+ precursors activate sirtuins?

This is the practical question most readers arrive with. The honest answer has several layers:

1. Biochemically, yes. Sirtuins are NAD+-limited at physiological substrate concentrations. The Km values for SIRT1, SIRT3, and SIRT6 are in the 100-500 μM range — close enough to measured tissue NAD+ concentrations that small changes in NAD+ should change reaction velocity. Raising NAD+ availability via NR, NMN, or niacin increases substrate for sirtuin catalysis.
2. In cells and tissues, mostly yes. Cantó et al. (2012, PMID: 22682224) showed NR supplementation in mice elevated mitochondrial NAD+ and improved muscle oxidative metabolism through a SIRT3-dependent mechanism. Mills et al. (2016, PMID: 28068222) showed NMN supplementation in aged mice raised tissue NAD+ and improved insulin sensitivity, mitochondrial function, and exercise endurance. These results are consistent with sirtuin activation but rarely measure sirtuin enzymatic activity directly.
3. In humans, the evidence is indirect. Martens et al. (2018, PMID: 29515118) showed 1 g/day NR for six weeks raised blood NAD+ ~60% and lowered systolic blood pressure in middle-aged adults. Yoshino et al. (2021, PMID: 33888596) showed 250 mg/day NMN for ten weeks improved muscle insulin sensitivity in pre-diabetic postmenopausal women. Elhassan et al. (2019, PMID: 31685596) showed 1 g/day NR for 21 days raised muscle NAD+ in aged men with transcriptomic shifts consistent with mitochondrial-program activation. None of these trials directly measured SIRT1, SIRT3, or SIRT6 enzymatic activity in tissue.
4. The bottleneck might be elsewhere. If CD38 activity is driving NAD+ decline by accelerated hydrolysis, raising NAD+ supply fights a leak rather than restoring source pressure. Whether precursor-driven NAD+ elevation reaches a high enough sustained level to meaningfully shift sirtuin output in aged tissue is an open quantitative question.

The cleanest summary: precursors raise NAD+, NAD+ is required for sirtuin function, and so the bridge is plausible. But moving from “biochemically required” to “clinically meaningful in healthy adults at supplemental doses” needs trials that directly assay sirtuin output, not just NAD+ levels or downstream biomarkers.

Exercise, caloric restriction, and sirtuin activation

The strongest non-pharmacological sirtuin activators are also the oldest. Endurance exercise raises NAD+ availability in skeletal muscle and concurrently increases SIRT1 and SIRT3 activity. Costford et al. (2010, PMID: 20660300) showed that exercise training in humans raises skeletal muscle SIRT3 protein levels. Caloric restriction in rodents elevates both SIRT1 and SIRT3 expression and reduces global mitochondrial acetylation.

For most outcomes researchers care about — insulin sensitivity, mitochondrial function, oxidative-stress defense — endurance exercise and moderate caloric restriction produce larger effect sizes than any sirtuin-targeting drug currently in human trials. This is not an argument against pharmacological approaches; it is context for what sirtuin activation can realistically achieve.

Sirtuin kinetics: why NAD+ concentration matters mechanistically

A small but important detail explains why NAD+ supplementation has any plausible reason to affect sirtuin output at all. Sirtuins are not saturated by NAD+ at typical cellular concentrations. Their Michaelis constants (Km) for NAD+ sit in a range close to measured intracellular NAD+ levels — meaning small changes in NAD+ concentration translate to roughly proportional changes in reaction velocity.

Published Km values vary by substrate and assay but typically fall in these ranges (Sauve and Youn 2012, PMID: 22863945; Feldman et al. 2015, PMID: 26015464):

• SIRT1: Km for NAD+ ~150-200 μM with peptide substrates. Intracellular NAD+ in liver is roughly 400-700 μM in young animals and 200-400 μM in aged animals.
• SIRT3: Km for NAD+ ~280-880 μM depending on substrate. Mitochondrial NAD+ may be lower than cytoplasmic pools, placing SIRT3 closer to its half-saturation point.
• SIRT6: Km for NAD+ ~25-30 μM for deacylation of long-chain fatty-acyl-lysine substrates, with much higher Km for acetyl-lysine substrates. SIRT6 is the sirtuin most likely to be NAD+-saturated under physiological conditions.

This kinetic picture is why the NAD+-sirtuin story is biochemically coherent but quantitatively uncertain. Sirtuins are nominally sub-saturated for NAD+ at aged-tissue concentrations, so raising NAD+ should raise activity. But the relationship is not linear once you account for product inhibition by nicotinamide (also rising in aged tissue) and competing NAD+ consumers (CD38, PARP) drawing from the same pool. The net effect on tissue-level sirtuin output is the sum of these moves, not the substrate-availability change in isolation.

Tissue-specific sirtuin biology

Sirtuin activity differs dramatically by tissue, and the aging-relevant story differs accordingly. A few highlights worth knowing if you read the literature critically:

Skeletal muscle

Skeletal muscle sirtuin biology is dominated by SIRT1 and SIRT3. SIRT1 in muscle deacetylates PGC-1α — the master mitochondrial biogenesis transcriptional coactivator — and is activated by endurance exercise and fasting. SIRT3 in muscle mitochondria controls fatty acid oxidation and oxidative phosphorylation efficiency. Muscle-specific SIRT1 knockout in mice reduces exercise capacity and impairs the metabolic adaptation to training. Muscle SIRT3 declines with age and is restored by exercise training (Lanza et al. 2012, PMID: 22275446).

Heart

Cardiac SIRT3 is the most-studied sirtuin in heart aging and heart failure. SIRT3 deacetylates SOD2, optic atrophy 1 (OPA1), and cyclophilin D — three proteins central to mitochondrial ROS defense, mitochondrial dynamics, and permeability transition. SIRT3 knockout mice develop accelerated cardiac hypertrophy under pressure overload (Sundaresan et al. 2009, PMID: 19620979). For interventions in cardiac aging, raising mitochondrial NAD+ to support SIRT3 is the most-supported single mechanism. (Our companion piece on NR in heart failure walks through the LVAD, HFrEF, and atrial fibrillation trial data.)

Brain

Brain sirtuin biology is less settled. SIRT1 in the hypothalamus regulates appetite and energy expenditure. SIRT3 in neurons protects against excitotoxic injury. SIRT6 in cortex maintains genomic stability — SIRT6-knockout mice show cognitive impairment and accelerated neurodegeneration markers. Whether NAD+ precursor supplementation reaches brain tissue at levels that affect neuronal sirtuin activity is an open question; blood-brain-barrier penetrance of NR and NMN is incompletely characterized.

Liver

Liver sirtuin activity is exquisitely fasting-responsive. Hepatic SIRT1 deacetylates PGC-1α and FOXO1 during fasting to switch the liver from glycolysis to gluconeogenesis and fatty acid oxidation. SIRT3 in hepatic mitochondria similarly upregulates fatty acid oxidation under fasting. This is one tissue where intermittent fasting and time-restricted eating have a clear sirtuin-mediated mechanistic explanation; SIRT1 activity in liver tracks the fed-fasted cycle in mice with remarkable fidelity.

Open questions and what to watch

Several active threads in sirtuin research will shape the next few years of NAD+ science:

• Tissue-specific sirtuin activators. Current STACs activate SIRT1 systemically. Tissue-targeted activators — for mitochondrial SIRT3 or skeletal-muscle SIRT1 — could produce cleaner effects without offsetting changes in other tissues.
• Sirtuin-CD38 crosstalk. Both consume NAD+. If CD38 activity rises with age and consumes the NAD+ that sirtuins would otherwise use, CD38 inhibition might raise sirtuin activity even without precursor supplementation. This is one of the strongest theoretical arguments for CD38 inhibitors.
• SIRT6 small-molecule activators.SIRT6 has the strongest direct lifespan evidence but the smallest pharmacological pipeline. Activators are technically harder to develop than SIRT1 STACs because SIRT6's structure does not present the same allosteric pocket.
• Acetylome readouts in human trials.Most NAD+ precursor trials measure blood NAD+. The next-generation question is whether elevated NAD+ shifts tissue acetylomes toward “younger” patterns. Mass-spectrometry acetylomics is becoming tractable in clinical samples.
• Sirtuin activity in disease. Beyond aging itself, SIRT3 reductions appear in heart failure, SIRT6 reductions in metabolic syndrome, and SIRT1 dysregulation in chronic kidney disease. Each condition is a more targeted test of whether sirtuin restoration produces benefit.

Bottom line

Sirtuins are the mechanistic reason NAD+ levels are interesting at all. They convert NAD+ availability into changes in transcription, DNA repair, mitochondrial efficiency, and inflammation. SIRT1, SIRT3, and SIRT6 dominate the longevity-relevant literature; SIRT6 has the clearest direct mammalian lifespan evidence to date.

Whether raising NAD+ via supplementation produces meaningful sirtuin activation in healthy adults is biochemically plausible but clinically unresolved. Most human trials of NR, NMN, and other precursors measure blood NAD+ and downstream phenotypes, not sirtuin enzymatic output. The gap between “NAD+ went up” and “sirtuins did more useful work” is the next several years of clinical research.

For now, the highest-confidence sirtuin activators remain the oldest: endurance exercise, energy restriction, and adequate sleep. Direct pharmacological activation of sirtuins is a real research program but has not produced a flagship clinical win after two decades. NAD+ precursors are an indirect approach with biochemical justification and an accumulating, but still inconclusive, human evidence base.